ライフサイエンスコーパス: arterial disease

1 ngina, stroke, heart failure, and peripheral arterial disease).

2 (smoking, diabetes mellitus, and peripheral arterial disease).

3 d CHD, stroke, heart failure, and peripheral arterial disease.

4 se risks can adversely affect progression of arterial disease.

5 disease and monitoring therapy in peripheral arterial disease.

6 stable coronary artery disease or peripheral arterial disease.

7 en, and patients with diabetes or peripheral arterial disease.

8 on differences in the location and extent of arterial disease.

9 e most efficacious treatments for peripheral arterial disease.

10 walking performance developed for peripheral arterial disease.

11 CHD), cerebrovascular disease and peripheral arterial disease.

12 -induced angiogenesis, such as in peripheral arterial disease.

13 on remains unclear in patients with manifest arterial disease.

14 d be extended to patients without peripheral arterial disease.

15 Q can be used in patients without peripheral arterial disease.

16 ith T2D that are related to early markers of arterial disease.

17 s, tobacco use, heart failure, or peripheral arterial disease.

18 d their receptors, adipokines, and miRNAs to arterial disease.

19 ty and mortality in patients with peripheral arterial disease.

20 nt hypertension, preeclampsia, or peripheral arterial disease.

21 pathy, ischemic heart disease and peripheral arterial disease.

22 age rates in patients with severe peripheral arterial disease.

23 artery of diabetic patients with peripheral arterial disease.

24 validated therapy for symptomatic peripheral arterial disease.

25 A for treatment of infrapopliteal peripheral arterial disease.

26 life-threatening complication of peripheral arterial disease.

27 in patients with symptomatic infrapopliteal arterial disease.

28 sease, heart failure, stroke, and peripheral arterial disease.

29 ase, cerebrovascular disease, and peripheral arterial disease.

30 nd surgical revascularization for peripheral arterial disease.

31 on is tissue- and life-saving in obstructive arterial disease.

32 unctional decline in persons with peripheral arterial disease.

33 ctional decline among people with peripheral arterial disease.

34 clinical imaging in patients with peripheral arterial disease.

35 carotid dissection, and, rarely, peripheral arterial disease.

36 e in persons with lower-extremity peripheral arterial disease.

37 r than revascularization for lower-extremity arterial disease.

38 ssion worsens vascular outcome in peripheral arterial disease.

39 Mac-1-deficiency did not prevent late graft arterial disease.

40 and leukocyte recruitment in lower-extremity arterial disease.

41 impaired in elderly patients with peripheral arterial disease.

42 alloon angioplasty for complex infrainguinal arterial disease.

43 nts underwent PER for symptomatic peripheral arterial disease.

44 ch as coronary artery disease and peripheral arterial disease.

45 ary heart disease, stroke, and/or peripheral arterial disease.

46 ood, track into adult life and contribute to arterial disease.

47 ch as coronary artery disease and peripheral arterial disease.

48 role in the development of severe pulmonary arterial disease.

49 hemic heart disease implying a role in human arterial disease.

50 ons in patients with asymptomatic peripheral arterial disease.

51 increased risks of venous thromboembolic and arterial disease.

52 art disease, ischemic stroke, and peripheral arterial disease.

53 ach in patients with advanced below-the-knee arterial disease.

54 hemia represents the end stage of peripheral arterial disease.

55 he limbs of certain patients with peripheral arterial disease.

56 ossible matches), 95% of whom had peripheral arterial disease.

57 ts with stable coronary artery or peripheral arterial disease.

58 od flow in selected patients with peripheral arterial diseases.

59 erapeutic target for combating proliferative arterial diseases.

60 al immunoprivilege or medial inflammation in arterial diseases.

61 articipation of inflammation and immunity in arterial diseases.

62 CI 0.86-0.98]) and strongest for peripheral arterial disease (1.23 [1.20-1.27]).

63 rior stroke/transient ischemic attack, 6.5%; arterial disease, 15.9%; all CHADS-VASc risk factors wer

64 on, of which the most common were peripheral arterial disease (16.2%, n=992) and heart failure (14.1%

65 with stent occlusion or stenoses, peripheral arterial disease (ABI <1.0), symptomatic cardiac disease

66 rongly positively associated with peripheral arterial disease (adjusted cause-specific hazard ratio 2

67 ars old with VTE had 3.3-fold higher risk of arterial disease (adjusted hazard ratio, 3.28; 95% confi

68 es was positively associated with peripheral arterial disease (adjusted HR 2.98 [95% CI 2.76-3.22]),

69 udy examined parenchymal rejection and graft arterial disease after total allomismatched cardiac tran

70 isease mortality and one study on peripheral arterial disease).All but one study reported positive as

71 on second exertion in patients with coronary arterial disease, also known as the warm-up angina pheno

72 m selenium with the prevalence of peripheral arterial disease among 2,062 US men and women 40 years o

73 m and lower limbs is a common consequence of arterial disease and a major source of morbidity and mor

74 s (coronary, cerebrovascular, and peripheral arterial disease and heart failure).

75 cal for blood flow restoration in peripheral arterial disease and is triggered by increasing fluid sh

76 LI) is the most advanced stage of peripheral arterial disease and is usually treated with bypass surg

77 a range of conditions, including peripheral arterial disease and myocardial infarction, where it has

78 ponse to ischemia associated with peripheral arterial disease and myocardial infarction.

79 al arterial revascularization for peripheral arterial disease and to assess whether readmission risk

80 as coronary, cerebrovascular, or peripheral arterial disease, and (2) incident heart failure.

81 ADA HbA1c clinical categories for peripheral arterial disease, and 0.683 for ADA fasting glucose conc

82 the absence of beta-blocker use, peripheral arterial disease, and a deeper prosthesis insertion are

83 with preserved ejection fraction, peripheral arterial disease, and abdominal aortic aneurysms, are al

84 disease, cerebrovascular disease, peripheral arterial disease, and all-cause cardiovascular disease,

85 disease, cardiovascular disease, peripheral arterial disease, and all-cause mortality than did fasti

86 med in patients with diabetes and peripheral arterial disease, and at least 25% require subsequent re

87 including coronary heart disease, peripheral arterial disease, and cerebrovascular disease, in an eld

88 ertension, myocardial infarction, peripheral arterial disease, and impaired renal function were signi

89 , carotid intima-media thickness, peripheral arterial disease, and pulse wave velocity).

90 infections-male sex, hypertension, coronary arterial disease, and serogroup C1 infections-were each

91 risks of coronary heart disease, peripheral arterial disease, and stroke.

92 ed diabetes mellitus, symptomatic peripheral arterial disease, and superficial femoral artery lesions

93 rapeutic efficacy of heparin in inflammatory arterial diseases, and nonanticoagulant heparin derivati

94 n, previous heart failure, MI, or peripheral arterial disease; and who received coronary artery bypas

95 e after myocardial infarction and peripheral arterial disease are predominant, devastating cardiovasc

96 Heart failure and peripheral arterial disease are the most common initial manifestati

97 the treatment of lower extremity peripheral arterial disease are typified with diminished patency.

98 ne in people with lower extremity peripheral arterial disease are unknown.

99 lae and smooth muscle cells (SMCs), and many arterial diseases are characterized by defective lamella

100 CLI is an advanced form of peripheral arterial disease associated with nonhealing arterial ulc

101 ss (IMT) is a noninvasive marker of systemic arterial disease, associated with atherosclerosis, abnor

102 s (ie, risk factors, coronary and peripheral arterial disease, asymptomatic carotid stenosis, and 10-

103 ment of patients with symptomatic peripheral arterial disease because they are associated with simila

104 Rates of evaluation for peripheral arterial disease before amputation were low, and testing

105 flow in an experimental model of peripheral arterial disease, by exploiting fluorescence in the NIR-

106 al artery revascularization, lower-extremity arterial disease, carotid endarterectomy or angioplasty,

107 ic medial arterial calcification (MAC) is an arterial disease commonly referred as Monckeberg's scler

108 he fully adjusted odds ratios for peripheral arterial disease comparing selenium quartiles 2, 3, and

109 brovascular, coronary artery, and peripheral arterial diseases) complications.

110 disease, cerebrovascular disease, peripheral arterial disease, congestive heart failure, malignant ve

111 Further they had more peripheral arterial disease, coronary artery disease, carotid steno

112 gous cell therapy for intractable peripheral arterial disease/critical limb ischemia.

113 , and race-adjusted prevalence of peripheral arterial disease decreased with increasing serum seleniu

114 Inflammatory arterial diseases differentially affect the compartments

115 tive imaging approach to evaluate peripheral arterial disease does not exist.

116 c heart disease, aortic aneurysm, peripheral arterial disease, endocarditis, and all other cardiovasc

117 Peripheral arterial disease epidemiology and/or management was repo

118 ase, acute myocardial infarction, peripheral arterial disease, epilepsy, substance abuse, heart failu

119 disease, diabetes mellitus, known peripheral arterial disease, evaluation by a vascular specialist, a

120 7 cerebrovascular disease, and 98 peripheral arterial disease events.

121 d 13 patients suspected of having peripheral arterial disease (five men; mean age, 67 years; age rang

122 sease (coronary artery disease or peripheral arterial disease) followed from 1997 to 2009, AF status

123 ysplasia (FMD) is a rare, nonatherosclerotic arterial disease for which the molecular basis is unknow

124 The SMART score (Second Manifestations of Arterial Disease) for 10-year risk of myocardial infarct

125 Graft arterial disease (GAD) limits long-term solid-organ allo

126 field of cell-based therapies for peripheral arterial disease has been in a state of continuous evolu

127 ease, including HTN, HF, CHD, and peripheral arterial disease, have a better prognosis compared with

128 r stable angina, ischemic stroke, peripheral arterial disease, heart failure, and cardiac arrest, to

129 rs include advanced age, smoking, peripheral arterial disease, high blood pressure, coronary artery d

130 .77; 95% CI, 0.62-0.94; P = .01), peripheral arterial disease (HR, 0.65; 95% CI, 0.49-0.87; P = .004)

131 2), heart failure (HR, 0.84), and peripheral arterial disease (HR, 0.85).

132 s noted for fractures (HR, 1.80), peripheral arterial disease (HR, 2.25), venous thromboembolism (HR,

133 nce interval [CI]: 1.82 to 2.29), peripheral arterial disease (HR: 1.95; 95% CI: 1.72 to 2.21), unher

134 infarction (HR=1.75, P=0.02), and peripheral arterial disease (HR=2.01, P=0.01).

135 disease, coronary artery disease, peripheral arterial disease, hypertension, pulmonary hypertension,

136 l injury and dysfunction precede accelerated arterial disease in allograft vasculopathy and systemic

137 y contribute to worse outcomes of peripheral arterial disease in patients with diabetes mellitus (DM)

138 nships of aPL with valvular, myocardial, and arterial disease in SLE.

139 dothelial dysfunction and the progression of arterial disease in the general population is unknown.

140 The age-adjusted prevalence of peripheral arterial disease in the US population has been estimated

141 The age-adjusted prevalence of peripheral arterial disease in the US population was estimated to a

142 Surgical treatment options for peripheral arterial disease include angioplasty, endarterectomy, an

143 linical consequences of occlusive peripheral arterial disease include intermittent claudication, that

144 linical consequences of occlusive peripheral arterial disease include pain on walking (claudication),

145 s was previously found to be associated with arterial diseases, including intracranial aneurysm.

146 The prevalence of peripheral arterial disease increases with the age of the populatio

147 Peripheral arterial disease is a common disease that has few treatm

148 Peripheral arterial disease is a major complication of diabetes.

149 Peripheral arterial disease is a manifestation of systemic atherosc

150 Peripheral arterial disease is associated with adverse cardiovascul

151 Peripheral arterial disease is largely considered to be a disease o

152 Because peripheral arterial disease is most commonly caused by atherosclero

153 Peripheral arterial disease is one manifestation of systemic athero

154 es, the overall population having peripheral arterial disease is predicted to rise.

155 erventions for lifestyle-limiting peripheral arterial disease is unknown.

156 te coronary syndrome, stroke, and peripheral arterial diseases, is a chronic progressive inflammatory

157 prognosis of myocardial ischemia, peripheral arterial disease, ischemic stroke, etc.

158 elation of alcohol intake to lower-extremity arterial disease (LEAD) have included clinical events an

159 rovide the opportunity to characterize early arterial disease long before cardiovascular complication

160 In patients with manifest arterial disease, low baseline DBP was associated with m

161 The Secondary Manifestations of ARTerial disease-Magnetic Resonance (SMART-MR) Study is

162 We hypothesized that in peripheral arterial disease, maladaptive changes in VEGF ligand/rec

163 Treatment of peripheral arterial diseases may be distinguished into conservative

164 For peripheral arterial disease, men with PLMI >/=30 compared with the

165 onditions that simulate tumor and peripheral arterial disease microenvironment.

166 to theorize why rates of various subtypes of arterial disease might vary across populations.

167 mouse hindlimb ischemia model of peripheral arterial disease, MITCH-PEG co-delivery of hiPSC-ECs and

168 tive sample size [n(e)] = 9,396); peripheral arterial disease (n(e) = 5,215); abdominal aortic aneury

169 mprehensive Magnetic Resonance of Peripheral Arterial Disease; NCT00587678).

170 [CI], 0.31-0.45; P=5.5*10(-26)], peripheral arterial disease (odds ratio 0.42; 95% CI, 0.26-0.68; P=

171 Patients with peripheral arterial disease often undergo peripheral endovascular r

172 ease, cerebrovascular disease, or peripheral arterial disease or with multiple risk factors for ather

173 coronary, cerebrovascular, and/or peripheral arterial) disease or multiple atherothrombotic risk fact

174 (OR, 0.58; 95% CI, 0.43-0.78) and peripheral arterial disease (OR, 0.43; 95% CI, 0.22-0.85) were less

175 se (OR, 0.12; 95% CI, 0.03-0.45), peripheral arterial disease (OR, 6.36; 95% CI, 1.56-25.87), and pro

176 without coronary artery disease, peripheral arterial disease, or diabetes mellitus.

177 patients with renal dysfunction, peripheral arterial disease, or following a brief P2Y12-receptor an

178 with prior myocardial infarction, peripheral arterial disease, or stroke.

179 nts with diabetes, heart failure, peripheral arterial disease, or tobacco use had the largest predict

180 ated with progression of preclinical carotid arterial disease over a 6-year period and was more close

181 cluding among individuals without peripheral arterial disease (P<0.001).

182 <0.0001), hypertension (P<0.001), peripheral arterial disease (P=0.0002), smoking (P<0.0001), and ele

183 Peripheral arterial disease (PAD) affects 5 million people in the U

184 rs explain the high prevalence of peripheral arterial disease (PAD) among African Americans.

185 respond poorly to treatments for peripheral arterial disease (PAD) and are more likely to present wi

186 nic arsenic exposure is linked to peripheral arterial disease (PAD) and cardiovascular disease.

187 king performance in patients with peripheral arterial disease (PAD) and intermittent claudication.

188 differences in the prevalence of peripheral arterial disease (PAD) and its associations with cardiov

189 Peripheral arterial disease (PAD) and osteoporosis are chronic illn

190 The ABI is used to diagnose peripheral arterial disease (PAD) and to identify those at risk for

191 ulate angiogenesis are altered in peripheral arterial disease (PAD) and whether these factors are ass

192 r cohort with a history of either peripheral arterial disease (PAD) and/or other cardiovascular disea

193 Patients with peripheral arterial disease (PAD) are at a high risk for cardiovasc

194 nvestigate the pathophysiology of peripheral arterial disease (PAD) by examining magnetic resonance i

195 Peripheral arterial disease (PAD) caused by occlusive atheroscleros

196 Peripheral arterial disease (PAD) causes significant morbidity and

197 dial infarction (MI), stroke, and peripheral arterial disease (PAD) during the subsequent 8 yr.

198 rtance: Patients with concomitant peripheral arterial disease (PAD) experience worse cardiovascular o

199 Patients with peripheral arterial disease (PAD) have high rates of adverse cardio

200 en and women with lower extremity peripheral arterial disease (PAD) have higher levels of inflammator

201 her prevalence of lower-extremity peripheral arterial disease (PAD) in black adults.

202 Cadmium has been associated with peripheral arterial disease (PAD) in cross-sectional studies, but p

203 steine levels are associated with peripheral arterial disease (PAD) in observational studies.

204 ; weight (kg)/height (m)(2)) with peripheral arterial disease (PAD) in prior studies may reflect lowe

205 tivity and functional capacity in peripheral arterial disease (PAD) in small, short-term studies.

206 Peripheral arterial disease (PAD) is a chronic, lifestyle-limiting

207 Peripheral arterial disease (PAD) is a clinical condition caused by

208 Peripheral arterial disease (PAD) is a clinical manifestation of ex

209 Peripheral arterial disease (PAD) is a costly source of morbidity a

210 Peripheral arterial disease (PAD) is a subclinical measure of ather

211 Peripheral arterial disease (PAD) is an important cardiovascular di

212 Lower-extremity peripheral arterial disease (PAD) is associated with decreased func

213 Peripheral arterial disease (PAD) is caused by atherosclerosis that

214 Peripheral arterial disease (PAD) is common but commonly unrecogniz

215 The prevalence of peripheral arterial disease (PAD) is increasing worldwide, with rec

216 disease, but its association with peripheral arterial disease (PAD) is unclear.

217 PURPOSE OF REVIEW: Peripheral arterial disease (PAD) is underdiagnosed, undertreated,

218 mmation in the pathophysiology of peripheral arterial disease (PAD) is well established, the contribu

219 antageous approach to symptomatic peripheral arterial disease (PAD) over the longer term.

220 antageous approach to symptomatic peripheral arterial disease (PAD) over the longer term.

221 an important role in determining peripheral arterial disease (PAD) pathology, which causes a spectru

222 0.1, mean age 30 +/- 7 years); 2) peripheral arterial disease (PAD) patients (n = 12; mean ABI 0.6 +/

223 emius biopsies from patients with peripheral arterial disease (PAD) predict mortality rates.

224 Genetic determinants of peripheral arterial disease (PAD) remain largely unknown.

225 amputation risk in patients with peripheral arterial disease (PAD) remains difficult.

226 Peripheral arterial disease (PAD) was defined by ankle brachial ind

227 urine cadmium concentrations with peripheral arterial disease (PAD) were evaluated by using data from

228 her patients with lower-extremity peripheral arterial disease (PAD) who are more physically active du

229 tion of progressive versus stable peripheral arterial disease (PAD) with the risk of future cardiovas

230 rength training for patients with peripheral arterial disease (PAD) without intermittent claudication

231 d that women with lower extremity peripheral arterial disease (PAD) would have greater mobility loss

232 ystem, but their association with peripheral arterial disease (PAD), a high-prevalence vascular illne

233 ma-based factors as predictors of peripheral arterial disease (PAD), and comparative data between ind

234 risk factors for atherosclerotic peripheral arterial disease (PAD), such as dyslipidemia, diabetes m

235 ment of patients with established peripheral arterial disease (PAD), the prevalence of PAD and associ

236 In participants with peripheral arterial disease (PAD), we determined whether more seden

237 hy for suspected or known chronic peripheral arterial disease (PAD), with contrast material-enhanced

238 ly performed for the treatment of peripheral arterial disease (PAD).

239 achial index (ABI) and those with peripheral arterial disease (PAD).

240 ality rates in men and women with peripheral arterial disease (PAD).

241 scular mortality in patients with peripheral arterial disease (PAD).

242 osis in patients with concomitant peripheral arterial disease (PAD).

243 sion in subjects with progressive peripheral arterial disease (PAD).

244 66 participants included 412 with peripheral arterial disease (PAD).

245 life in asymptomatic persons with peripheral arterial disease (PAD).

246 , ischemic stroke, or symptomatic peripheral arterial disease (PAD).

247 hort of patients with symptomatic peripheral arterial disease (PAD).

248 h in persons with lower extremity peripheral arterial disease (PAD).

249 among persons with versus without peripheral arterial disease (PAD).

250 sing avenue for the management of peripheral arterial disease (PAD).

251 a to lower limbs in patients with peripheral arterial disease (PAD).

252 nd amputation among patients with peripheral arterial disease (PAD).

253 ysiological angiogenesis to treat peripheral arterial diseases (PAD) by increasing the vascular endot

254 e impact of polyvascular disease (peripheral arterial disease [PAD] and cerebrovascular disease [CVD]

255 The study population included 203 peripheral arterial disease participants who underwent vertical acc

256 Peripheral arterial disease patients included those with intermitte

257 In femoropopliteal arterial disease, PCB therapy is associated with superio

258 important for the large number of peripheral arterial disease persons without access to supervised wa

259 ery disease, limb ischemia due to peripheral arterial disease, pressure-overload heart failure, wound

260 In spline regression models, peripheral arterial disease prevalence decreased with increasing se

261 Peripheral arterial disease prevalence ranged from 3.1% to 24% of a

262 including hypertension, diabetes, peripheral arterial disease, previous myocardial infarction, angina

263 mellitus, hypertension, smoking, peripheral arterial disease, previous stroke, previous coronary byp

264 Atherosclerosis is an arterial disease process characterized by the focal sube

265 This arterial disease process impairs the supply of oxygen an

266 linical CVD but with asymptomatic peripheral arterial disease, regardless of its low CVD risk.

267 re patients who underwent a major peripheral arterial disease-related amputation during the period be

268 scular care and regional rates of peripheral arterial disease-related amputation.

269 on, the most common of which were peripheral arterial disease (reported in 992 [16.2%] of 6137 patien

270 Peripheral Arterial Disease Research Coalition (Europe).

271 Atherosclerosis in the form of peripheral arterial disease results in significant morbidity.

272 y treatment for patients with infrapopliteal arterial disease reveal suboptimal procedural and 1-year

273 , atrial fibrillation, aortic and peripheral arterial disease, rheumatic heart disease, and endocardi

274 tions to prevent mobility loss in peripheral arterial disease should focus on reversing pathophysiolo

275 ic obstructive pulmonary disease, peripheral arterial disease, smoking, diabetes, renal failure, hype

276 96%; LR, 3.1 [95% CI, 2.0-4.7]), peripheral arterial disease (specificity, 97%; LR, 2.7 [95% CI, 1.5

277 cal limb ischemia have severe below-the-knee arterial disease that limits the use of bypass surgery o

278 uscular dysplasia (FMD) is a noninflammatory arterial disease that predominantly affects women.

279 of non-atherosclerotic and non-inflammatory arterial diseases that primarily involves the renal and

280 surgical therapy for coronary and peripheral arterial disease, the burden of these illnesses remains

281 ended for secondary prevention in peripheral arterial disease, their effectiveness in CLI is uncertai

282 valent condition for coronary and peripheral arterial diseases, these findings create a paradox where

283 res is increased in patients with peripheral arterial disease, thus increasing the incidence of repor

284 l infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or

285 hundred seventy participants with peripheral arterial disease underwent baseline measurement of calf

286 Any fractures, peripheral arterial disease, venous thromboembolism, cardiac-relate

287 Peripheral arterial disease was defined as an ankle-brachial blood

288 nium levels and the prevalence of peripheral arterial disease was not statistically significant, alth

289 dy, 141 patients with symptomatic peripheral arterial disease were assigned to treatment with heparin

290 coronary artery bypass graft, and peripheral arterial disease were associated with prescription of as

291 ial, 76 patients with symptomatic peripheral arterial disease were randomized 2:1 to receive a helica

292 cular ejection fraction <20%, and peripheral arterial disease were significant predictors of mortalit

293 ptions for diabetic patients with peripheral arterial disease when revascularization is not possible

294 ngina, myocardial infarction, and peripheral arterial disease, whereas raised diastolic blood pressur

295 ronic coronary, intracranial, and peripheral arterial diseases, which together account for the leadin

296 hospitalizations of patients with peripheral arterial disease who had peripheral arterial revasculari

297 More than 1 in 6 patients with peripheral arterial disease who undergo peripheral arterial revascu

298 rial in symptomatic patients with peripheral arterial disease who underwent endovascular treatment fo

299 hospitalizations of patients with peripheral arterial disease who were discharged alive after periphe

300 e traditional focus of immunopathogenesis of arterial disease, with the goal of integrating the playe